PAR-25-335: NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) (PAR-28-072). Status: Due dates in the notice, expires November 16, 2029. It is in our archive of National Institutes of Health notices from 2025.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on March 16, 2025.
From the official notice on Grants.gov, last changed January 7, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNEI
- Median yearly award$709,450
- Typical project length2 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under PAR-25-335 were run by National Eye Institute (NEI, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-335 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-28-072 | September 25, 2026 | Due dates in the notice, expires November 16, 2029 | Open |
| PAR-23-200 | June 27, 2023 | Closed January 6, 2025 | Closed |
Key dates
| Posted | January 7, 2025 |
|---|---|
| Deadline | March 16, 2025 |
| Archived by Grants.gov | April 21, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Is this a realistic fit?
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.
Funded under PAR-25-335 so far
NIH funded 2 projects under PAR-25-335 in fiscal 2026, at 2 institutions. The median yearly award was $709,450.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Small molecule drugs for early-onset vitelliform macular dystrophy | Columbia University Health Sciences | 2026 | $740,700 |
| Development of a Novel Antimicrobial Drug Combination for the Treatment of Bacterial Keratitis | University of Rochester | 2026 | $678,201 |
Who has won Vision Research grants before
From fiscal 2021 to 2025, Vision Research (93.867) awarded $3.4 billion across 3,275 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 137 | $139 million |
| The Leland Stanford Junior University | California | 87 | $96.5 million |
| The Regents of the University of California, San Francisco | California | 78 | $89.9 million |
| Duke University | North Carolina | 79 | $75.5 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 57 | $73.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-28-072, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-335 still open?
No. It closed on March 16, 2025. A newer notice is open: PAR-28-072, due dates in the notice, expires November 16, 2029.
Who can apply for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)?
Closed March 16, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-25-335?
NIH RePORTER lists 2 projects funded under PAR-25-335 in fiscal 2026, at 2 institutions. The most were at Columbia University Health Sciences, University of Rochester.
Who has won Vision Research grants before?
The largest recipients over five fiscal years were The Johns Hopkins University, The Leland Stanford Junior University, The Regents of the University of California, San Francisco. The program made 3,275 awards worth $3.4 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)